Fertility Preservation in Breast Cancer Patients Under Special Consideration of Ovarian Stimulation for Fertility Purposes

Main Article Content

Sebastian Findeklee https://orcid.org/0000-0002-2921-0664
Sebastian Grewe
Klaus Diedrich


breast cancer, gonadotoxic effects, fertility preservation, oncofertility, ovarian stimulation




1. Weiss T. Ökonomische Bestimmungsgrößen der Fertilität in westlichen Industrieländern. Bundesinstitut für Bevölkerungsforschung; 1996
2. Menken J, Trussell J, Larsen U. Age and infertility. Science 1986; 233:1389-1394
3. Mattle V, Behringer K, Engert A, Wildt L. Female fertility after cytotoxic therapy-protection of ovarian function during chemotherapy of malignant and non-malignant diseases. Eur J Haematol Suppl 2005;77-82
4. Anderson RA, Wallace WH, Baird DT. Ovarian cryopreservation for fertility preservation: indications and outcomes. Reproduction 2008;136:681-689
5. Lee MC et al. Fertility and reproductive considerations in premenopausal patients with breast cancer. Cancer Control 2010;17(3):162-172
6. Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pacific journal of cancer prevention (APJCP) 2016;17:43-46
7. Radecka B, Litwiniuk M. Breast cancer in young women. Ginekologia polska 2016;87:659-663
8. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Annals of oncology : official journal of the European Society for Medical Oncology 1990;1:183-188
9. Sukumvanich P, Case LD, Van Zee K, Singletary SE, Paskett ED, Petrek JA et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer 2010;116:3102-3111
10. Kleinstein J. GnRH-Analoga und Add-back-Verfahren. J Gyn Endokrinol 2008;2(2):40-43
11. von Wolff M, Dian D. Fertility Preservation in Women With Malignant Tumors and Gonadotoxic Treatments. Dtsch Ärztebl Int 2012;109(12):220-226
12. Arbeitsgemeinschaft Gynäkologische Onkologie. Kommission Mamma. Diagnostik und Therapie früher und fortgeschrittener Mammakarzinome; 2020
13. Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertility and sterility 2013;100:1673-1680
14. von Wolff M, Capp E, Jauckus J, Strowitzki T, Germeyer A, Ferti Psg. Timing of ovarian stimulation in patients prior to gonadotoxic therapy: an analysis of 684 stimulations. Eur J Obstet Gynecol and Reprod Biol 2016;199:146-149
15. von Wolff M, Dittrich R, Liebenthron J, Nawroth F, Schuring AN, Bruckner T et al. 2015. Fertility-preservation counselling and treatment for medical reasons: data from a multinational network of over 5000 women. Reprod Biomed Online 2015;31:605-612
16. von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM et al. Ovarian stimulation to
cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertility and
steril 2009;92:1360-1365
17. Moffat R, Pirtea P, Gayet V, Wolf JP, Chapron C, de Ziegler D. Dual ovarian stimulation is a new viable option for enhancing the oocyte yield when the time for assisted reproductive technnology is limited. Reprod Biomed Online 2014;29:659-661
18. Turan V, Bedoschi G, Moy F, Oktay K. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertil Steril 2013;100:1681-1685e1
19. Zhang J. Luteal phase ovarian stimulation following oocyte retrieval: is it helpful for poor responders? Reprod Bbiology Endocrinol 2015; 13:76
20. Lawrenz B, Jauckus J, Kupka M, Strowitzki T, von Wolff M. Efficacy and safety of ovarian stimulation before chemotherapy in 205 cases. Fertil Steril 2010;94:2871-2873
21. Diaz-Garcia C, Domingo J, Garcia-Velasco JA, Herraiz S, Mirabet V, Iniesta I et al. Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: a prospective cohort study. Fertil Steril 2018;109:478-485e2
22. Register DI. 2018. 16. Jahrgang 2019 // Modifizierter Nachdruck aus Nummer 6: 279–315 // ISSN 1810-2107. Journal of Reproductive Medicine and Endocrinology
23. Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F. Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer. Journal of Clinical Oncology 2015;33:2424-2429
24. Haas J, Bassil R, Meriano J, Samara N, Barzilay E, Gonen N et al. Does daily co-administration of letrozole and gonadotropins during ovarian stimulation improve IVF outcome? Reprod Biol Endocrinol 2017;15:70
25. Kim J, Turan V, Oktay K. Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer. The Journal of clinical endocrinology and metabolism 2016;101:1364-1371
26. Sharma S, Ghosh S, Singh S, Chakravarty A, Ganesh A, Rajani S et al. Congenital malformations among babies born following letrozole or clomiphene for infertility treatment. PloS one 2014;9:e108219
27. Findeklee S, Radosa JC, Takacs Z, Hamza A, Sima RM, Solomayer EF et al. Fertility preservation in female cancer patients: current knowledge and future perspectives. Minerva Ginecol 2019;71(4):298-305
28. Regan MM, Walley BA, Francis PA, Fleming GF, Láng I, Gómez HL et al. Concurrent and
sequential initiation of ovarian function suppression with chemotherapy in
premenopausal women with endocrine-responsive early breast cancer: an exploratory
analysis of TEXT and SOFT. Annals of oncology 2017;28:2225-2232
29. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) DGfRD, Deutsche
Gesellschaft für Urologie (DGU). Leitlinie: Fertilitätserhaltung bei onkologischen
Therapien. Level S2k, AWMF Register Nr. 015/082;2017
30. Dolmans MM, Masciangelo R. Risk of transplanting malignant cells in cryopreserved
ovarian tissue. Minerva Ginecol 2018;70:436-443